Outlook maintained for the full-year ̶ soft quarter Q3 report 2019/20 February 20, 2020
Agenda 1. Q3 performance 2. Financials 3. Outlook 4. Q&A 3 3
Important information This presentation includes forward-looking statements including, but not limited to, statements relating to operational and financial performance, market conditions, and other similar matters. These forward- looking statements are based on current expectations about future events. Although the expectations described in these statements are assumed to be reasonable, there is no guarantee that such forward- looking statements will materialize or are accurate. Since these statements involve assumptions and estimates that are subject to risks and uncertainties, results could differ materially from those set out in the statement. Certain of these risks and uncertainties are described further in the Annual Report in section “Risks and uncertainties”. Elekta undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or stock exchange regulations. This presentation is intended for investors and analysts only. Some products are still in research and/or not cleared/approved in all markets. Cancer statistics are given to show the potential market in the respective area and does not mean that Elekta currently has products to treat these indications. 4
1. Q3 performance Dr. Richard Hausmann President and CEO 5
We are Precision. Radiation. Medicine. Everyone with cancer should have access to and benefit from precise, personalized radiotherapy 6
Driving innovation and thought leadership MR-Linac paradigm shift Integration of ProKnow • • Centralize, archive, view and analyze Elekta Unity superior high-field system treatment planning data • Excellent clinical results from 20 Elekta • Automated metrics and performance Unity systems scorecards Acquiring remaining • Collaboration with ViewRay to drive • Cloud base scalable framework share of Palabra market adoption Apps integrated in MOSAIQ Plaza • Smart Clinic • Voice Automation • Teleport 7
Elekta supporting World Cancer Day Uppsala univeristy hospital promoting Elekta Unity in Sweden Joint quest against women cancer in Vienna 8 Inauguration of 1st (Elekta) linac in Rwanda
Strong interest at Arab Health • Exciting meetings with customers and partners • Signing of multiple orders with customers across the region 9
Q3 – Improved profitability but weak order intake Key Q3 financials • Organic order intake -11% • Organic net sales +5% • Gross margin 42.0% (40.7) • EBITA margin 17.7% (15.2) 10 10
Q3 – Improved profitability 9M – Confidence in full-year but weak order intake outlook Key Q3 financials Key 9M financials • Organic order intake -11% • Organic order intake +6% • Organic net sales +5% • Organic net sales +7% • Gross margin 42.0% (40.7) • Gross margin 41.8% (40.5) • EBITA margin 17.7% (15.2) • EBITA margin 15.4% (15.8) Get in high resolution 11 11
Creating value by innovation and thought leadership EBITA margin Net sales rolling 12 months rolling 12 months MSEK 20 000 20% Orders 16 000 15% Net sales 12 000 10% 8 000 5% 0% 4 000 16/17 17/18 18/19 19/20 16/17 17/18 18/19 Q319/20 12
Q3: Strong order growth in EMEA and China North & Europe, Middle Asia South America East & Africa (EMEA) Pacific -43% 9% -6% • Negative development in the US • Strong growth both in mature and emerging • Strong order growth in China, driving the region markets continuing taking market shares, being clear market leader • Good contribution from Brazil • Big bundle deal win Jules Bordet/Belgium and Colombia • Large bundle deal of 10 linacs including 1 Elekta Unity and 4 linac-deal to university hospital Dresden to private HEDY Group/China • Larry Biscotti heading Region North and Central America • Several linac orders in Russia • Exciting win, HCM Oncology Hospital in Vietnam • 1 st LGK order to Dubai • Strong success in Nigeria, ordered 4 linacs 13 Q3 growth rates based on constant exchange rates
9M: Double-digit order growth in EMEA and Asia Pacific North & Europe, Middle Asia South America East & Africa (EMEA) Pacific -10% +11% +15% 14 9M figures based on constant exchange rates
Elekta Unity – 65 systems ordered as of today Reiterating 75 orders by Mid-2020 – most likely already at the end of the FY 19/20 North & Europe, Middle Asia South America East & Africa (EMEA) Pacific +1 Q3 30 21 14 Total 15
Elekta Unity demo in Tübingen in November: Two oligomets in one session - adapting to the antonomy of the day Oligomet no. 1 Oligomet no. 2 Fraction n Fraction n+1 Rektum Rektum Courtesy: Dr. Gani, University of Tübingen
Partial breast irradiation (PBI) Post Operative PBI Insufficient target visualization with CT following breast reconstruction Registration CBCT/ planning CT Planning CT Target area clearly visualized with MR IMRT SnS Plan, 40.05 Gy /15 fx ATP workflow with MM (avg. 20mins) Registration daily MR / planning CT Planning MR Reference: Nachbar M et al. Partial breast irradiation with the 1.5 T MR-Linac: First patient treatment and analysis of electron return and stream effects. Radiotherapy and Oncology. 2019;145:30–35.
Our Elekta Unity pioneers treating patients routinely 20 installed Elekta Unity systems in clinical use with great feedback on performance 1) 1) 1) 1) 1) 1) 1) Shandong Cancer Hong Kong Sana- Hospital & Institute torium & Hospital 1) 18 1) Original consortium members
2. Financials Gustaf Salford CFO 19
Strong service revenue growth and margin improvement Q3 Q3 • Net sales up 5% for the quarter (SEK M) 2019/20 2018/19 • Solutions +3% and Service +8% Net sales 3,320 3,656 Solutions 2,216 2,049 • North and South America: -23% Service 1,440 1,270 • Europe Middle East and Africa: +25% COGS -2,121 -1,967 • Asia Pacific: +19% Gross margin (%) 42.0% 40.7% Expenses* -851 -782 • Gross Margin improvement Exchange diff and other -36 -66 • Supported by Neuro and Oncology Information EBITA 648 505 System growth EBITA margin (%) 17.7% 15.2% • COGS reduction program contributing Amortization -205 -194 EBIT 443 311 • EBITA at 17.7% Net financial items -45 -39 • Improvement vs. last year and last quarter Income taxes -89 -60 Net profit 308 212 • Net Profit growth of 45% EPS 0.81 0.55 20 * Excluding amortization
Continued focus on cost control Capitalization and amortization Expenses Q3 vs. LY* 250 vs. Q2* (SEK M) 2019/20 197 185 183 176 200 175 166 Selling -339 5% -6% 135 132 128 150 124 104 101 97 Administrative -282 10% -4% 120 100 R&D (Net) -415 -1% -1% 50 0 Total -1,036 4% -4% Q1 18/19Q2 18/19 Q3 18/19Q4 18/19Q1 19/20 Q2 19/20Q3 19/20 Capitalization Amortization • Increased selling expenses to drive growth and Unity • Net R&D decreased as capitalization increased opportunities more than amortization vs LY driven by late-stage • Administrative expense increase driven by R&D projects investments in IT solutions/operational excellence • Gross R&D in relation to net sales at 10% and costs for litigation 21 * Constant currency
Volume and product mix main driver of increased EBITA margin Q3 YTD - EBITA bridge (SEK M) 15.8% 15.0% 15.4% • Strong contribution from 142 197 volume and product mix 109 455 163 86 • Last year the MEG 70 divestment contributed 80 bps to EBITA 1635 1492 1422 • On EBITA level currencies had a negative SEK -40 M YTD (and SEK +50 M in the quarter) EBITA Q3 MEG excl. MEG Volume Product Mix Unity Admin / FX rate Amortization EBITA Q3 18/19 divestment Sales Exp / Other differences 19/20 Amortization Expenses 22
Net working capital reflecting Brexit inventory and invoicing seasonality Net working capital change in the quarter Net working capital as % of sales 9,741 68 125 Q1 Q2 Q3 Q4 Q1 Q2 Q3 9,374 18/19 18/19 18/19 18/19 19/20 19/20 19/20 398 Assets 88 0% -2% Q2 19/20 Inventory Accounts Accrued Other Q3 19/20 -5% receivable income -7% -7% -10% -9% 10,345 -13% -15% 176 -14% 10,104 Liabilities -15% 21 309 223 -20% Key focus areas in Q4 quarters Q2 19/20 Customer Accounts Prepaid Other Q3 19/20 • Get rid of Brexit inventory Advances payable income • Collect on high invoice volumes generated in Q3 23
3. Outlook Dr. Richard Hausmann President and CEO 24
Measures to further improve profitability and cash flow Continue COGS improvement in Drive strong Get rid of Profitability improvements Drivers invoicing and installations Brexit inventory kick in collection process Strong installations Currently worked Increased gross Improvement, Current except in the US, margin, reaching down and shipped to more work needed status especially in OIS and customers 42% Elekta Unity Deliver on plan and Continue draw Zero Brexit Improvements Regional targets and optimize global benefit from COGS inventory at in Q4 central support resources program end of April accordingly 25
Recommend
More recommend
